Traveka Wealth
VRTX icon

Traveka Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Traveka Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$260K Buy
498
+94
+23% +$48.1K 0.08% 166
2026
Q2 		$201K Buy
+404
New +$179K 0.07% 192
2025
Q2 		– Sell
-422
Closed -$205K – 157
2025
Q1 		$205K Buy
+422
New +$197K 0.11% 138

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Traveka Wealth's VRTX Position: Q3 2026 in Review

Traveka Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 23% in Q3 2026, buying an estimated $48.1K and bringing the position to 498 shares worth $260K. The position accounts for 0.08% of the portfolio, ranked #166.

Traveka Wealth first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Traveka Wealth held 498 shares of Vertex Pharmaceuticals worth $260K as of Q3 2026.
  • Traveka Wealth bought 94 Vertex Pharmaceuticals shares in Q3 2026, an estimated $48.1K.
  • Vertex Pharmaceuticals made up 0.08% of Traveka Wealth's portfolio in Q3 2026, its #166 holding.
  • Traveka Wealth first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Traveka Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.